Wall Street Zen downgraded shares of SBC Medical Group (NASDAQ:SBC – Free Report) from a strong-buy rating to a buy rating in a report published on Saturday,Wall Street Zen reports.
SBC has been the topic of a number of other research reports. BTIG Research reiterated a “buy” rating and issued a $8.00 price target on shares of SBC Medical Group in a research report on Thursday, August 13th. Weiss Ratings raised SBC Medical Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, October 9th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.
Read Our Latest Report on SBC Medical Group
SBC Medical Group Stock Performance
Shares of SBC Medical Group stock opened at $6.18 on Friday. The stock has a market cap of $635.61 million, a price-to-earnings ratio of 11.36, a P/E/G ratio of 2.40 and a beta of 0.52. SBC Medical Group has a twelve month low of $2.78 and a twelve month high of $7.39. The company’s fifty day moving average is $5.17 and its 200 day moving average is $3.98. The company has a quick ratio of 3.27, a current ratio of 3.31 and a debt-to-equity ratio of 0.09.
SBC Medical Group (NASDAQ:SBC – Get Free Report) last announced its earnings results on Friday, November 13th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.03. The business had revenue of $58.58 million during the quarter, compared to analyst estimates of $48.90 million. SBC Medical Group had a return on equity of 18.47% and a net margin of 27.99%. Sell-side analysts forecast that SBC Medical Group will post 0.44 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of SBC Medical Group in the 2nd quarter worth approximately $2,846,000. Russell Investments Group Ltd. boosted its stake in shares of SBC Medical Group by 2,810.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 125,991 shares of the company’s stock valued at $622,000 after purchasing an additional 121,662 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of SBC Medical Group in the 3rd quarter valued at $520,000. Citadel Advisors LLC acquired a new stake in shares of SBC Medical Group during the second quarter worth $446,000. Finally, State Street Corp increased its position in shares of SBC Medical Group by 58.9% during the third quarter. State Street Corp now owns 78,232 shares of the company’s stock worth $386,000 after buying an additional 28,993 shares during the period. Institutional investors and hedge funds own 60.82% of the company’s stock.
SBC Medical Group Company Profile
SBC Medical Group Holdings provides management and support services to medical institutions, with a focus on clinics offering aesthetic medicine. Its services include support for clinic operations, marketing, staff training, procurement and customer service, allowing affiliated medical providers to focus on patient care. The group is associated with the Shonan Beauty Clinic brand and a broader network of clinics offering services such as cosmetic surgery and dermatology. Its business is centered primarily in Japan, where it supports the operations and growth of affiliated medical institutions.
Further Reading
- Five stocks we like better than SBC Medical Group
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for SBC Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SBC Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
